Home Page

HONG KONG, April 24, 2014 /PRNewswire/ --

OrbusNeich today announced the appointment of B. Wayne Johnson as president and chief operating officer and the expansion of its board of directors with the additions of Scott Addonizio, vice president & general manager, Shenzhen operations; David Camp, vice president, sales & marketing, Europe, the Middle East and Africa (EMEA); and Christophe Lee, vice president and chief financial officer.

Mr. Johnson has more than 32 years of medical device experience, primarily in the areas of general management, operations and product development. He was previously senior vice president and chief operating officer of OrbusNeich. Prior to joining OrbusNeich, he was president and chief executive officer of Sutura Inc., a development stage company based in Fountain Valley, Calif., focused on commercializing suture-mediated wound closure products. Preceding Sutura, he was president and chief executive officer of Prostec LLC (a division of Syntheon LLC), dedicated to devices for prostate brachytherapy. Before Prostec, he was employed by Cordis for 18 years, during which time he held various roles of increasing responsibility, including vice president and general manager of the company's largest facility. He was also a member of the Cordis operating board as vice president of worldwide operations.

Since 2012 he has been a member of the board of directors of Microvisk Technologies Ltd., a U.K.-based company developing medical diagnostic devices. He holds a B.S. in biology and both an MBA and an M.S. degree in management from Rensselaer Polytechnic Institute.

"Throughout their tenure with OrbusNeich, Scott, David and Christophe have been instrumental in the growth and progress of the company," said Mr. Johnson. "As members of the board of directors, they will certainly provide valuable insight and perspective at this dynamic time in the company's development as we focus on sales of the COMBO Dual Therapy Stent™ and on other value creation projects in order to maximize the return for our investors."

Mr. Addonizio has more than 19 years of medical device experience with companies including Boston Scientific and Cordis. He joined Orbus as a project manager and is the primary holder of the "stent having dual helical design" patent, which is the backbone of all OrbusNeich stent platforms. In 2005, he was appointed director & general manager, Shenzhen operations, leading operations and product development efforts.

Mr. Camp has more than 26 years of medical device experience, working with companies such as Cordis and Spectranetics. He co-founded Orbus Medical Technologies in 1996 and served as president and chief executive officer. He was instrumental in developing and commercializing various technologies. After the merger of Orbus and Neich Medical in 2005, he has served in various roles, most recently as vice president, sales and marketing for the EMEA.

Mr. Lee has more than 21 years of experience in the financial services sector. Prior to joining OrbusNeich, he worked at FrontPoint Partners, Sun Hung Kai Financial, Goldman Sachs and Bankers Trust. Mr. Lee served as the Chairman of the Hong Kong Chapter of the Alternative Investment Management Association (AIMA) from 2003-2012. He was appointed by the HKSAR government to serve on the Advisory Committee of the Securities and Futures Commission (SFC) from 2007 to 2009, and, since March 2013, to serve on the Financial Services Development Council. He was also a member of the Hong Kong Trade Development Council Financial Services Advisory Committee from 2007 to 2011.

About OrbusNeich 

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first dual therapy stent, the COMBO Dual Therapy Stent, and the world's first pro-healing stent, the Genous™ Stent. Other products include stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit http://www.OrbusNeich.com.

Follow OrbusNeich on Twitter at http://www.twitter.com/OrbusNeich, and learn more about the company and its innovative technology on OrbusNeich's YouTube Channel: http://www.youtube.com/user/OrbusNeichMedia.

SOURCE OrbusNeich